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http://dx.doi.org/10.1016/j.jmii.2013Background/Purpose: Human herpesvirus 8 (HHV-8), the causal agent of Kaposi’s sarcoma (KS),
is transmitted sexually among men who have sex with men (MSM), but little is known of its
transmission among injection drug users (IDUs). By contrast, human parvovirus B19 (B19), a
causative agent for anemia, is most frequently detected in IDUs. The aim of this study was
to investigate the associations between HHV-8 infection and human immunodeficiency virus
type 1 (HIV-1), and between B-19 and HIV-1 among MSM and IDUs patients.
Methods: Serum samples from 553 IDUs and 231 MSM were analyzed for anti-HHV-8 lytic and
anti-B19 viral structural capsid protein 2 (VP-2) antibodies using enzyme immunoassay, indirect
immunofluorescence, and immunoblot assays. Odds ratios (ORs) and 95% confidence intervals
(CIs) were used to evaluate the associations between different viral infections.tion and Research Center, National Yang-Ming University, Taipei 112, Taiwan.
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234 Y.-M. Lee et al.Results: HIV-1-seropositive MSM had significantly higher rates of HHV-8 infection than serone-
gative MSM (32.3% and 15.4%, respectively; OR Z 2.62, 95% CI Z 1.37e5.02). Among HIV-1/
AIDS patient groups, MSM had significantly higher HHV-8 seropositive rates (32.3% vs. 6.6%,
p < 0.0001) and lower B19 infection rates (35.4% vs. 78.8%, p < 0.001) than IDUs. In addition,
HIV-1-infected MSM were 5.95 times (95% CI Z 3.38e10.46) more likely to be infected
with HHV-8 than male HIV-1-infected IDUs. By contrast, male IDUs were 6.74 times odds
(95% CI Z 4.28e10.61) more likely to contract B19 infection than MSM.
Conclusion: In Taiwan, MSM have a significantly higher prevalence for HHV-8 than IDUs. The
contrasting risks of HHV-8 and B19 infections between different HIV-1/AIDS groups suggest that
the efficiency of viral infection is affected by their distinct transmission routes.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus 8 (HHV-8), was discovered in
1994 and is the causative agent of Kaposi’s sarcoma (KS),
primary effusion lymphoma (PEL), and multicentric Cas-
tleman’s disease.1 Among HIV-1 exposure categories at risk
of AIDS KS in North America and Europe, the prevalence of
HHV-8 shows a distinct spread. Within a defined geo-
graphical area, this prevalence is highest among HIV-1-
infected men who have sex with men (MSM), lower
among HIV-1-infected injection drug users (IDUs) or HIV-1-
infected non-IDU heterosexual individuals, and lowest
among children.2,3 Interestingly, in one US region, the
HHV-8 prevalence rates among young MSM (15e22 years
old) were comparable with the rates among young heter-
osexual men, and both were noticeably lower than rates
among older MSM in that region.4 Moreover, HHV-8
acquisition has been associated with multiple sex part-
ners among both MSM and heterosexuals, and practices
involving saliva are thought to increase transmission,
which may account for differences in incidence of HHV-8
and HIV.5,6 International studies have provided some evi-
dence that HHV-8 can be transmitted by blood or blood
products.7,8 Atkinson et al also showed that longer dura-
tion of injection drug use is associated with an increase in
the risk of HHV-8 infection that is not explained by sexual
behavior or demographic differences.7 Among IDUs, while
syringe sharing is a common means of transmitting HIV-1,
hepatitis B virus (HBV), and hepatitis C virus, it may also
result in the spread of HHV-8.9
Human parvovirus B19 (B19) can cause a common
childhood disease with symptoms of exanthema and fever
known as erythema infectiosum.10 B19 has a strong tissue
tropism for erythroid progenitor cells and can cause ane-
mia. Study of occult B19 infection is recommended in
patients with hematological disease.11 In common with
other latent viruses such as herpesviruses, infections with
parvovirus B19, HBV, and hepatitis GB virus C (HGBV-C) are
contained successfully by the immune response and persist
in the host. When immune control breaks down, reac-
tivation of both latent and persistent viruses occurs.12,13
The background seroprevalence in blood donors is high for
B19 (64%), HBV (70%), CMV, and EBV (90%), and is
significantly increased in individuals infected with HIV, HBV,
cytomegalovirus (CMV), varicella-zoster virus (VZV;symptomatic HIV), and HHV-8 (asymptomatic and sympto-
matic HIV).14,15 Persistent parvovirus B19 infection has
been reported in patients both with and without underlying
immunodeficiencies.16e18 Antibody prevalence provided an
estimate of viral exposure and allowed adjustment for the
prevalence of potential reactivation to be calculated as
well as the odds ratios (ORs) for reactivation in susceptible
individuals. Levels of exposure among susceptible HIV-
infected patients to parvovirus B19 are comparable to
those for HIV-negative controls, because this infection is
transmitted via the respiratory route.19 Previous studies
also demonstrated that prolonged parvovirus infection with
anemia in HIV-infected patients was typically associated
with the absence of an antibody response to B19.20 In this
study, we compared the seroprevalence of HHV-8 and B19
infection between MSM and IDU groups among HIV-1/AIDS
patients in Taiwan.
Materials and methods
Subjects
This cross-sectional study was conducted among subjects
from the following three populations: 553 inmates who had
history of using injection drugs were recruited from
detention centers and prisons in Taiwan21,22; 127 HIV-1-
infected MSM were selected randomly from 879 patients
attending the outpatient clinics of Taipei City Hospital from
2004 to 2006, and 104 HIV-1 seronegative MSM were ran-
domly selected from 1093 patrons from gay saunas in Tai-
wan.23 Their HIV status and demographic data were
recorded by reviewing their medical history or assessed
through a self-administered questionnaire. Informed con-
sent was obtained from all participants and this study was
approved by the Institutional Review Board of the National
Yang-Ming University. Plasma samples were obtained from
the subjects for serological testing. The samples were
processed and stored at 80 C.
Serological testing
Sera were tested for HHV-8 antibodies by HHV-8 whole virus
lytic immunoglobulin G (IgG) enzyme-linked immunosorb-
ent assay (ELISA; Advanced Biotechnologies Inc., Columbia,
MD, USA)24,25 and indirect fluorescent assay (IFA; Advanced
Biotechnologies Inc., Columbia, MD, USA),26,27 which
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subjects were also screened for viral protein 2 (VP-2)
antibodies against human parvovirus B19 by Parvo B19 IgG
EIA and Parvo Blot IgG (Biotrin international Ltd., Dublin,
Ireland).28,29 These assays were performed according to the
protocols provided by manufacturers.Statistical analysis
Univariate analysis was performed using either Pearson c2
test or Fisher’s exact test as appropriate in order to detect
statistical significances when comparing HIV-1-seropositive
and HIV-1-seronegative subjects from the MSM and IDU
groups. Student t test was used to compare the mean ages
between the HIV-1-seropositive and HIV-1-seronegative
subjects from the MSM and IDU groups. ORs and 95% con-
fidence intervals (CIs) were used to evaluate theTable 1 Demographic characteristics of the study subjects
MSM (N Z 231)
HIV-1()
(N Z 104) n (%)
HIV-1(þ)
(N Z 127) n (%)
Gender
Male 104 (100) 127 (100)
Female 0 (0) 0 (0)
Age (y) n Z 80 n Z 127
20e29 27 (33.8) 56 (44.1)
30e39 35 (43.8) 61 (48.0)
40e49 10 (12.5) 8 (6.3)
50 8 (10.0) 2 (1.6)
Mean age 34.6  10.4 31.0  7.0
Education n Z 68 n Z 125
Informal/primary 1 (1.5) 1 (0.8)
Junior high 4 (5.9) 3 (2.4)
Senior high 38 (55.9) 35 (28.0)
College/university
/graduate school
25 (36.8) 86 (68.8)
Marital status n Z 68 n Z 124
Single 57 (83.8) 117 (94.4)
Married/cohabiting 9 (13.2) 5 (4.3)
Divorced/separated 2 (2.9) 2 (1.6)
Widowed 0 (0) 0 (0)
CD4 counts n Z 126
200 d 3 (2.4)
201e350 d 35 (27.8)
351e500 d 36 (28.6)
>500 d 52 (41.3)
Mean  SD 498.9  234.8
HIV-1 viral load n Z 125
50 d 60 (48.0)
51e500 d 22 (17.6)
501e10,000 d 13 (10.4)
>10,000 d 30 (24.0)
Mean  SD 17,635  51,110
ART n Z 125
Yes d 88 (70.4)
No d 37 (29.6)
ART Z antiretroviral therapy; IDUs Z injection drug users; MSM Z m
*The p values are only presented as the statistical significance betweassociation between HIV-1 and HHV-8 or HIV-1 and B19. The
Breslow-Day method was used to test the homogeneity of
the ORs between the MSM and IDU groups. SAS statistical
software (SAS version 9.1; SAS Institute Inc., Cary, North
Carolina, USA) was used for all analyses. Statistical sig-
nificance was set at p < 0.05.
Results
Demographic characteristics of the subjects who
participated in this study
In total, 784 subjects (504 HIV-1-seropositive and 280 HIV-1-
seronegative) participated in this study. Table 1 compares
the demographic characteristics of the MSM and IDU groups.
The male to female ratio of the IDU population was 3.8:1.
The mean age of the study population was 33.8  7.9 yearsIDUs (N Z 553)
p HIV-1()
(N Z 176) n (%)
HIV-1(þ)
(N Z 377) n (%)
p
d 127 (72.2) 310 (82.2) 0.0067
49 (27.8) 67 (17.8)
0.0124 n Z 176 n Z 374 0.2515
47 (26.7) 117 (31.3)
76 (43.2) 166 (44.4)
50 (28.4) 80 (21.4)
3 (1.7) 11 (2.9)
0.0076 35.0  7.0 34.7  7.7 0.1694
0.0003 n Z 176 n Z 368 0.0258
12 (6.8) 39 (10.6)
82 (46.6) 191 (51.9)
73 (41.5) 108 (29.4)
9 (5.1) 30 (8.2)
0.0495 n Z 176 n Z 374 0.3245
92 (52.3) 222 (59.4)
32 (18.2) 64 (17.1)
52 (29.6) 87 (23.3)
0 (0) 1 (0.3)
d n Z 159 0.0423*
d 16 (10.1)
d 37 (23.3)
d 52 (32.7)
d 54 (34.0)
441.5  194.2 0.0280*
d n Z 45 0.2419*
d 17 (37.8)
d 5 (11.1)
d 8 (17.8)
d 15 (33.3)
27,094  83,614 0.4791*
d n Z 356 <0.0001*
d 62 (17.4)
d 294 (82.6)
en who have sex with men; d Z not detected.
en HIV-1-seropositive MSM and IDUs.
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(34.3  7.5 vs. 32.4  8.6, pZ 0.0047). Approximately half
of MSM [111/193 (57.5%)] had college degree or post-
graduate education, but 92.8% of IDUs had received edu-
cation up to senior high school. A larger percentage of MSM
[174/192 (90.6%)] were single, while more than 20% of IDUs
were divorced or separated. Of the HIV-1-seropositive
subjects, 70.4% (88/125) of the MSM group were receiving
antiretroviral therapy (ART), but only 62 IDUs (17.4%) were
receiving ART (p < 0.0001). Although HIV-1 viral load did
not differ significantly among two groups, MSM group had a
significantly higher CD4 than IDUs (p Z 0.0280).
The associations between HHV-8 and HIV-1, and
between B19 and HIV-1 infection among MSM and
IDUs
Overall, HHV-8 prevalence was 24.68% (57/231) among
MSM, and 4.88% (27/553) among IDUs (p < 0.0001). HHV-8
infection was more prevalent among MSM, particularly in
young people, while HHV-8 seroprevalence in IDUs
increased in middle-aged people (Fig. 1A). The prevalenceFigure 1. Age-dependent seroprevalence of viruses for men
who have sex with men (MSM) and injection drug users (IDUs) in
Taiwan (NZ 784). Bar graphs depict the seroprevalence of (A)
human herpesvirus 8 (HHV-8) and (B) parvovirus B19 (B19)
infection. The number of subjects in each group is shown above
each bar.of B19 in IDUs [428/553 (77.40%)] was twice as high as that
in MSM [92/231 (39.83%)] (p < 0.0001). Across different age
groups, B19 infection remained relatively common in IDUs
(Fig. 1B). The associations between HHV-8 and HIV-1
infection in MSM and IDUs were determined. As shown in
Table 2, the HIV-1-seropositive subjects had significantly
higher HHV-8 infection rate than the HIV-1-seronegative
subjects among the MSM (32.3% vs. 15.4%, OR Z 2.62,
95% CI Z 1.37e5.02) and IDUs (6.6% vs. 1.1%, OR Z 6.18,
95% CI Z 1.45e26.38). Although the ORs were not stat-
istically significant in B19 infection, the infection rate was
lower among HIV-1-seropositive MSM (35.4% vs. 45.2%,
ORZ 0.67, 95% CIZ 0.39e1.13), while it was higher among
HIV-1-seropositive IDUs (78.8% vs. 74.4%, OR Z 1.28; 95%
CI Z 0.84e1.94). When we analyzed the associations only
in male subjects, MSM had 5.95 times higher (95%
CI Z 3.38e10.46) odds of being infected with HHV-8 than
IDUs (Table 3). By contrast, IDUs had 6.74 times higher odds
(95% CI Z 4.28e10.61) of being infected with B19 than
MSM. Of the 504 HIV-positive patients from whom HHV-8
and B19 titers were determined, CD4 cell counts and HIV
viral load were available for only 285 (56.5%) and 170
(33.7%), respectively. After adjustment for age, CD4 cell
counts, and receipt of highly active antiretroviral therapy
(HAART) among male HIV-1-infected subjects, MSM had 3.34
times higher (95% CI Z 1.45e7.66) odds of being infected
with HHV-8 than IDUs, and IDUs had 4.31 times higher (95%
CIZ 2.31e8.07) odds of being infected with B19 than MSM.Discussion
In this study, we conducted a seroepidemiological study to
investigate the prevalence of anti-HHV-8 lytic and anti-B19
VP-2 antibodies among HIV-1/AIDS patients. Antibody
testing in this cross-sectional study provides snapshots of
the MSM and IDUs populations that are the main high risk
groups in Taiwan. We found that HIV-1-seropositive sub-
jects had a higher seroprevalence rate for HHV-8 than HIV-
1-seronegative subjects [66/504 (13.1%) vs. 18/280 (6.4%)],
while the prevalence of anti-B19 antibodies was almost the
same between HIV-1-seropositive and HIV-1-seronegative
subjects [342/504 (67.9%) vs. 178/280 (63.6%)] (Table 2). In
addition, MSM had a significantly higher HHV-8 infection
rate than IDUs among HIV-1/AIDS patients (32.3% vs. 6.6%).
Previous reports have shown that high HHV-8 seropreva-
lence rates occur among HIV-infected patients in Africa,
Western countries, and Taiwan.2,3,30,31 HHV-8 seropreva-
lence varies greatly depending on the study population in
Taiwan, specifically 83.3% in KS(þ)/HIV() patients, 40% in
KS()/HIV(þ) patients, 24.5% in patients with hemato-
logical disorders, 23% in blood donors, 20.6% when there is
sexual contact, 19.5% in hemodialysis patients, and 12.9% in
non-KS cancer patients.31e34 In previous studies of Taiwan,
IFA was the common method used to detect HHV-8 antibody
titers against latent, lytic antigens, or recombinant pro-
teins [open reading frame 16 (ORF16), ORF57, and ORF71]
of HHV-8. 31,33e35 However, one study demonstrated that
HHV-8 antibodies are detected more frequently in HIV-
infected IDUs using the recombinant antigen ORF66 (lytic
and latent antigen)- and ORFK12 (latent antigen)-based
Western blot strip assays and ELISA.32 They reported that
Table 2 The association between HIV-1 and HHV-8 and HIV-1 and B19 in MSM and IDUs in Taiwan
HHV-8 OR (95% CI) Parvovirus B19 OR (95% CI)
þ  þ 
MSM
HIV-1(þ) (N Z 127) 41 (32.3%) 86 (67.7%) 2.62 (1.37e5.02) 45 (35.4%) 82 (64.6%) 0.67 (0.39e1.13)
HIV-1() (N Z 104) 16 (15.4%) 88 (84.6%) 1 47 (45.2%) 57 (54.8%) 1
IDUs
HIV-1(þ) (N Z 377) 25 (6.6%) 352 (93.4%) 6.18 (1.45e26.38) 297 (78.8%) 80 (21.2%) 1.28 (0.84e1.94)
HIV-1() (N Z 176) 2 (1.1%) 174 (98.9%) 1 131 (74.4%) 45 (25.6%) 1
HHV-8 Z human herpesvirus 8; IDUs Z injection drug users; MSM Z men who have sex with men; OR Z odds ratio.
Table 3 HHV-8 and B19 infection rates among male HIV-1-infected subjects in Taiwan
HHV-8 OR (95% CI) Parvovirus B19 OR (95% CI)
þ  þ 
MSM (N Z 127) 41 (32.3%) 86 (67.7%) 5.95 (3.38e10.46)a 45 (35.4%) 82 (64.6%) 1
IDUs (N Z 310) 23 (7.4%) 287 (92.6%) 1 244 (78.7%) 66 (21.3%) 6.74 (4.28e10.61)a
a Before adjustment. If adjusted by age, CD4 cell counts, and receipt of HAART, the ORs for HHV-8 and B19 seropositivity were 3.34
(95% CI Z 1.45e7.66) and 4.31 (95% CI Z 2.31e8.07), respectively.
HHV-8 Z human herpesvirus 8; IDUs Z injection drug users; MSM Z men who have sex with men; OR Z odds ratio.
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and specificity, and surveyed the seroprevalence of HHV-8
antibodies in HIV-1-infected subjects who attended hospi-
tal in the central region of Taiwan in 2005. In the present
study, we used commercially available ELISA and IFA, which
detected antibodies against lytic antigens of HHV-8, and
conducted a seroepidemiological study among subjects
recruited fromdetection centers, gay saunas, and STD clinics
in different geographic areas of Taiwan. Yang et al reported
that 79.4% of HHV-8 antibody-positive sera belonged to
IDUs,32 while only 37.9% of HHV-8 antibody-positive sera
belonged to IDUs in our study. The difference in the HHV-8
seroprevalence rates reported in the present study and
previous reports in Taiwan is probably due to changes in the
antigens and diagnostic methods used for the detection of
HHV-8 antibodies, or alternatively the study population
recruited in different geographic areas of Taiwan.
Among HIV-infected individuals, increased seropreva-
lence may be due to a sharing of transmission routes. In the
present study, we found that HHV-8 antibodies were
detectable more frequently among MSM (OR Z 5.95), but
B19 seroprevalence was higher among IDUs (OR Z 6.74)
(Table 3). Based on sexual behavior and method of drug
use, MSM and IDUs in Taiwan are two entirely different
groups. Sexual behavior is considered as the predominant
route of HHV-8 transmission in MSM, while blood-borne
transmission is considered the main route of B19 trans-
mission in IDUs. Although HHV-8 can be transmitted by both
sexual contact and blood,2,3,8 the efficiencies of HHV-8 and
B19 infection seems to have opposite levels of efficiency
between the different transmission routes. However, it
should be noted that the order of the viral infection is
unknown in this cross-sectional study. Thus, in terms of this
limitation, individuals could have been infected with HHV-8
or B19 before being infected with HIV-1 in a sexual rela-
tionship with a virus-bearing patient or by direct contactwith respiratory secretions or blood. Another limitation was
that there was too much missing data of the virologic and
immunologic parameters among IDUs. Further longitudinal
follow-up studies that overcome the methodological limi-
tations described above are needed to address the causal
relationship between HIV-1 and HHV-8/B19 infection.
In conclusion, the results show that MSM had significantly
higher prevalence rates of HHV-8 infection than IDUs in
Taiwan. The opposing levels of risk that are present for
HHV-8 and B19 infection in different groups suggest that the
efficiency of viral infection is affected by the distinct
transmission routes of the two viruses.Conflicts of interest
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